St. Jude Medical, citing results of a cost-effectiveness trial of its PressureWire fractional flow reserve device, says new data from a clinical trial shows it's more cost-effective than medical treatment alone.

St. Jude Medical's Fame II FFR study

St. Jude Medical (NYSE:STJ) is once again touting results from its Fame II study, this time citing data showing the cost-effectiveness of its PressureWire fractional flow reserve device.

The St. Paul, Minn.-based medical device company funded the trial, comparing patients who underwent percutaneous coronary intervention guided by FFR and "optimal medical therapy" (an anti-platelet and beta blocker drug regimen) with patients treated with drug therapy alone.

St. Jude lauded earlier data from the trial in August, saying Fame II demonstrated that the FFR-guided PCI arm patients fared better than the control arm. Now the company said the data also show that the procedure is less expensive than medical therapy alone over the long term.